会员体验
专利管家（专利管理）
工作空间（专利管理）
风险监控（情报监控）
数据分析（专利分析）
侵权分析（诉讼无效）
联系我们
交流群
官方交流：
QQ群： 891211   
微信请扫码    >>>
现在联系顾问~
下载
著录项
PDF全文
热词
    • 2. 发明申请
      US20080193484A1 Novel Methods for Producing Adenoviral Vector Preparations with Reduced Replication-Competent Adenovirus Contamination and Novel Adenoviral Vectors and Preparations 审中-公开
    • Novel Methods for Producing Adenoviral Vector Preparations with Reduced Replication-Competent Adenovirus Contamination and Novel Adenoviral Vectors and Preparations
    • 用于产生具有降低复制型腺病毒污染和新型腺病毒载体和制剂的腺病毒载体制备物的新方法
    • US20080193484A1
    • 2008-08-14
    • US11666221
    • 2005-10-25
    • Xinzhong Wang , George C. Kaynor , James Barsoum
    • Xinzhong Wang , George C. Kaynor , James Barsoum
    • A61K39/00 , C12N15/00 , C12N5/00 , A61K48/00
    • C12N15/86 , A61K48/00 , A61K2039/53 , C12N2710/10343 , C12N2830/42 , C12N2840/203
    • This invention provides novel replication-defective adenoviral vectors comprising an adenoviral genome in which the protein IX gene, preferably under the control of its own promoter, is in an inverted orientation relative to the direction of transcription of the native protein IX gene at a location where the protein IX gene normally resides, for production of replication-competent adenovirus (RCA) free, or substantially RCA-free, adenovirus preparations. Said vector preferably encodes a gene of interest. The invention relates to viral particles, host cells and compositions comprising said adenoviral vector. This invention further relates a method for propagating adenovirus preparations, free, or substantially free, of replication-competent adenovirus (RCA) particles, from host cells comprising vectors of this invention, for use to treat a subject suffering from a disease or disorder or to prevent a subject from getting a disease or disorder, such as cancer. The invention also provides methods of treating such subjects and methods of prophylactically treating unaffected subjects. This invention further provides for vaccine compositions comprising the novel replication-defective adenoviral vectors of the present invention.
    • 本发明提供了新的复制缺陷型腺病毒载体，其包含腺病毒基因组，其中优选在其自身启动子控制下的蛋白质IX基因相对于天然蛋白IX基因转录方向处于倒置方向， 蛋白质IX基因通常存在，用于产生无复制的腺病毒（RCA）或基本上不含RCA的腺病毒制剂。 所述载体优选编码感兴趣的基因。 本发明涉及包含所述腺病毒载体的病毒颗粒，宿主细胞和组合物。 本发明还涉及从包含本发明载体的宿主细胞中扩增游离或基本上游离的具有复制能力的腺病毒（RCA）颗粒的腺病毒制剂的方法，用于治疗患有疾病或病症的受试者或 防止受试者患有疾病或病症，如癌症。 本发明还提供了治疗这些受试者的方法和预防性治疗未受影响的受试者的方法。 本发明进一步提供包含本发明的新型复制缺陷型腺病毒载体的疫苗组合物。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
    • 5. 发明申请
      US20090042991A1 Methods of increasing natural killer cell activity for therapy 审中-公开
    • Methods of increasing natural killer cell activity for therapy
    • 增加治疗自然杀伤细胞活性的方法
    • US20090042991A1
    • 2009-02-12
    • US11918354
    • 2006-04-13
    • James Barsoum , Zhenjian Du
    • James Barsoum , Zhenjian Du
    • A61K31/15
    • A61K31/165 , A61K31/16 , Y02A50/402 , Y02A50/409 , Y02A50/415 , Y02A50/423 , Y02A50/47 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/49 , Y02A50/491 , Y02A50/492
    • Methods of employing bis(thio-hydrazide amides) to increase NK cell activity in a subject in need thereof, e.g., a subject with an infection or an immunodeficiency, are provided such that the disorder is not cancer, a proliferative cell disorder, a non-infective heat shock protein 70 (Hsp70) responsive disorder, or a proteasome-inhibitor responsive disorder. Typically, a subject, e.g., a human, can be in need of increased NK cell activity has an immunodeficiency or is treated for an infection (e.g., a bacterial, viral, fungal, or parasite infection, or a combination thereof). The method includes administering to the subject an effective amount of a compound represented by Structural Formula I: Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.
    • 提供了使用双（硫代酰肼）酰胺来增加有需要的受试者例如具有感染或免疫缺陷的受试者的NK细胞活性的方法，使得该病症不是癌症，增殖性细胞病症， - 感染性热休克蛋白70（Hsp70）反应性病症或蛋白酶体抑制剂反应性病症。 通常，受试者（例如人）可能需要增加的NK细胞活性具有免疫缺陷或被治疗用于感染（例如细菌，病毒，真菌或寄生虫感染或其组合）。 该方法包括向受试者施用有效量的由结构式I表示的化合物：Y是共价键或任选取代的直链烃基，或Y与它们同时存在的两个> C = Z基团一起 是任选取代的芳族基团。 R 1 -R 4独立地是-H，任选取代的脂族基团，任选取代的芳基，或者R 1和R 3与它们所键合的碳原子和氮原子一起，和/或R 2和R 4与碳和 与它们键合的氮原子形成任选地与芳环稠合的非芳族杂环。 R 7 -R 8独立地为-H，任选取代的脂族基团或任选取代的芳基。 Z是O或S.
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
    • 7. 发明申请
      US20060142386A1 Bis(thio-hydrazide amides) for increasing Hsp70 expression 有权
    • Bis(thio-hydrazide amides) for increasing Hsp70 expression
    • 用于增加Hsp70表达的双（硫代酰肼酰胺）
    • US20060142386A1
    • 2006-06-29
    • US11281923
    • 2005-11-17
    • James Barsoum
    • James Barsoum
    • A61K31/275 , A61K31/16
    • A61K45/06 , A61K31/16 , A61K31/165 , A61K31/275 , A61K31/277 , A61K2300/00
    • A method of treating a Hsp70-responsive disorder in a subject includes administering to the subject an effective amount of a compound represented by Structural Formula I, or a pharmaceutically acceptable salt or solvate thereof. Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.
    • 治疗受试者中Hsp70反应性障碍的方法包括向受试者施用有效量的由结构式I表示的化合物或其药学上可接受的盐或溶剂化物。 Y是共价键或任选取代的直链烃基，或Y与它们所键合的两个> C = Z基团一起是任选取代的芳族基团。 R 1 -R 4独立地是-H，任选取代的脂族基团，任选取代的芳基或R 1和R 2 > 3，它们与它们所键合的碳原子和氮原子一起，和/或R 2和R 4与碳和氮原子一起 形成与芳环稠合的非芳族杂环。 R 7 -R 8独立地是-H，任选取代的脂族基团或任选取代的芳基。 Z是O或S.
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
每页展示10个专利
每页展示10个专利
每页展示20个专利
每页展示50个专利
每页展示100个专利

IPRDB

最新中国发明专利 最新美国发明专利 技术领域 专利库 专利分类库 国际专利分类库

热门服务

会员版试用 API 数据接口 找代理 知嘟嘟专利交易 排行榜 大学排行榜 专利百科

关于我们

平台介绍 战略合作 网站地图

友情链接

知嘟嘟专利交易 国家知识产权局 中国商标网

联系方式


©2019-2023 上海吉码数字技术有限公司 版权所有，并保留所有权利 沪ICP备20016256号-6 沪公网安备31011702005475号